42 results about "Plasma Exchanges" patented technology

Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g. blood, of a patient. In particular, the methods are based on the administration of compounds capable of binding to amyloid-beta (Aβ) or on dialysis of blood or plasma exchange in order to remove Aβ peptides from the blood circulation, and / or brain or other affected organs.

The invention discloses a plasma exchanging adsorption filtration purification system provided with a plasma storage bag and an application method of the purification system. The method includes two steps of plasma components separation returning cycle and high-speed plasma purification regeneration cycle. Plasma components are separated by a selective membrane plasma separator; flow speed difference between a plasma separation cycle and a plasma purification circle is set by the specific plasma storage bag; high-speed plasma adsorption filtration purification treatment is performed by a high-throughput filter and an active carbon-resin absorptive device in a purification circle; and plasma subjected to cycle treatment for multiple times can be exchanged back to a human body through the separation returning circle. By the aid of the purification system and the application method thereof, autologous plasma waste generated in a plasma exchanging purification process can be purified continuously and effectively, and plasma consumption is reduced. The high-throughput filter and an adsorption column are connected in series to purify the plasma; load on a subsequent adsorber is reduced; and varied inflammatory factors, macromolecular toxins and the like combined by micromolecules, middle molecules and proteins which are generated from hepatic failure are eliminated as well, so that the purification efficiency of the whole system is greatly improved.

The invention discloses an extracorporeal circulation pipeline of a plasma exchange device capable of switching blood separators in order to solve the problem that due to blocking of blood separators, artificial liver treatment is forced to interrupt in the artificial liver treatment technical process. The extracorporeal circulation pipeline comprises a blood circulation system, a liquid supplement system, a liquid discharge system, the standby blood separator and a pipeline body, wherein the blood circulation system is composed of a blood inlet pipeline, a blood pump, the blood separators and a blood return pipeline, the liquid supplement system comprises an exchange liquid container, a liquid inlet pipeline and a liquid pump, the liquid discharge system comprises a liquid discharge pipeline, a plasma pump and a waste liquid collection container, and the standby blood separator can be supported to cut into the extracorporeal circulation pipeline immediately through the pipeline body when the blood separators in use are blocked. Thus, the problem that due to blocking of the blood separators, artificial liver treatment is forced to interrupt in the artificial liver treatment technical process is solved.

The invention discloses an application of a plasma-free replacement liquid composition in preparation of a medicine for removing M protein of multiple myeloma. Plasma exchange treatment can be carriedout on a multiple myeloma case with the plasma-free replacement fluid. The plasma-free replacement liquid composition comprises three parts which are equal in quantity, are independently prepared andare separately used, wherein the three parts are respectively 0.9% normal saline, equilibrium liquid and 4% albumin normal saline, the equilibrium liquid is sodium lactate Ringer's liquid, and the preparation method of the 4% albumin normal saline comprises the step of adding 100ml of 20% albumin into 400ml of normal saline. Compared with the prior art, the blood sedimentation index, the renal function index and the blood high-viscosity state of a patient can be effectively improved compared with those before treatment, and the patient does not have serious adverse reaction after treatment. The application of the plasma-free replacement liquid taking albumin as the main component remarkably reduces the dosage of fresh frozen plasma, and the plasma-free replacement liquid composition has clinical popularization value.